2030242-21-6: Enzalutamide Inhouse Impurity L

Enzalutamide Inhouse Impurity L (CAS No.2030242-21-6) or 4-(3-(4-Carbamoyl-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide. Enzalutamide is a nonsteroidal antiandrogen that binds to the ligand-binding domain and has more affinity. It is used in the treatment of castration-resistant prostate cancer.

Additional information

Catalogue No.

VE008226

CAS No.

2030242-21-6

Molecular Formula

C21H18F4N4O3S

Molecular Weight

482.45 g/mol

IUPAC Name

4-(3-(4-Carbamoyl-3-(trifluoromethyl)phenyl)-5, 5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide

References

"Schrader, Andres Jan, et al. “Enzalutamide in Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel and Abiraterone.” European Urology, vol. 65, no. 1, Jan. 2014, pp. 30–36, https://doi.org/10.1016/j.eururo.2013.06.042. ?Graff, Julie N., et al. “Early Evidence of Anti-PD-1 Activity in Enzalutamide-Resistant Prostate Cancer.” Oncotarget, vol. 7, no. 33, July 2016, pp. 52810–17, https://doi.org/10.18632/oncotarget.10547. ?"

Status

In-stock